Health Highlights: Dec. 14, 2022
New drug might be an advance against eczema. Rocatinlimab is a monoclonal antibody that researchers found prevented the recurrence of the symptoms of the skin condition for up to 20 weeks after treatment was stopped. Read more
Move to electric cars will save lives and billions in health care costs. Replacing vehicles powered by gas and diesel with electric ones will pay big dividends for Americans' health, a new study finds. Read more
Big U.S. genetics study is already helping participants. Called "All of Us," the study aims to eventually include at least 1 million people, in an effort to accelerate medical breakthroughs. Read more
Long COVID has taken the lives of more than 3,500 Americans. Research is revealing that the damage caused by a COVID infection poses a long-term risk to some who survive their bout with the coronavirus. Read more
Related Posts
IVIg Reduces Infection Rate in Multiple Myeloma Patients Receiving Anti-BCMA Therapy
THURSDAY, Oct. 5, 2023 (HealthDay News) -- Many patients with multiple myeloma...
La fluticasona, un medicamento para el asma, fracasa como tratamiento potencial para la COVID
JUEVES, 14 de julio de 2022 (HealthDay News) -- El furoato de fluticasona, un...
Adverse Postoperative Outcomes Not Increased With Recent COVID-19
TUESDAY, March 28, 2023 (HealthDay News) -- Recent COVID-19 infection seems not...
Poor Outcomes Common With COVID-19, Acute Ischemic Stroke
FRIDAY, Feb. 18, 2022 (HealthDay News) -- About half of patients with COVID-19...